News & Updates
Filter by Specialty:
Use of monitoring tests remains low in prostate cancer
Low use of recommended monitoring tests, including repeat prostate biopsy, persists among patients with localized prostate cancer undergoing observation, a recent study has found.
Use of monitoring tests remains low in prostate cancer
23 Mar 2023Response to therapy higher in clinical trial than real-world RCC patients
Among patients with metastatic renal cell carcinoma (RCC) who have received first-line therapies, complete response rates are lower in the real-world population than in the clinical trial population, reports a recent study. Complete response predicts a favourable overall survival.
Response to therapy higher in clinical trial than real-world RCC patients
22 Mar 2023CBT, mindfulness help improve sexual outcomes in prostate cancer
Mindfulness and cognitive behavioural therapy (CBT) appear beneficial for prostate cancer survivors and their partners who are dealing with sexual dysfunction, a study has shown.
CBT, mindfulness help improve sexual outcomes in prostate cancer
21 Mar 2023SC trastuzumab cost-saving for HER2-positive breast cancer in Hong Kong
A cost minimization analysis based on a literature review and Hong Kong data suggests that using subcutaneous (CS) instead of intravenous (IV) trastuzumab for HER2-positive breast cancer (BC) patients can offer an annual saving of more than USD 8.3 million to the Hong Kong healthcare system.
SC trastuzumab cost-saving for HER2-positive breast cancer in Hong Kong
20 Mar 2023Frequent aspirin use protects against ovarian cancer even in women with genetic predisposition
Genetic susceptibility to ovarian cancer does not appear to modify the protective association between frequent aspirin use and the risk of developing the cancer, as shown in a study.
Frequent aspirin use protects against ovarian cancer even in women with genetic predisposition
19 Mar 2023Cyclophosphamide-free adjuvant chemo works against ERBB2-negative breast cancer
The adjuvant chemotherapy regimen epirubicin plus paclitaxel (EP) appears to be as good as the regimen that consists of epirubicin and cyclophosphamide followed by paclitaxel (EC-P) in the treatment of Asian women with operable ERBB2-negative breast cancer, according to the results of an open-label phase III trial.